I. Borrello
Immunology · 2006–2016
A researcher in the Science corpus: 8 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 61 citations into it; #1,095 of 2,160 by trust here, #732 by citations
Whom I. Borrello trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- D. Gabrilovich (in Immunology)
- V. Bronte (in Immunology)
Who trusts I. Borrello
- M. Munder (in Immunology)
- D. Gabrilovich (in Immunology)
- V. Bronte (in Immunology)
Papers from I. Borrello's perspective
Ordered by how strongly the researchers I. Borrello trusts endorse each paper. Same corpus, a different order for every researcher.
- Immunosuppressive networks in the tumour environment and their therapeutic relevance (Nature Reviews. Cancer)
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function (Journal of Experimental Medicine)
- Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 (Journal of Immunology)
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. (Journal of Clinical Investigation)
- Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. (New England Journal of Medicine)
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer (Nature Medicine)
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy (Nature Medicine)
- Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
- Mechanisms and functional significance of tumour-induced dendritic-cell defects (Nature reviews. Immunology)
- Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. (Cancer Research)
Their papers
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function (2006) — 770 citations
- Myeloid derived suppressor cells promote cross-tolerance in B cell lymphoma by expanding regulatory T cells (2008) — 688 citations
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016) — 938 citations
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014) — 3,318 citations
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. (2008) — 1,805 citations
- Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. (2007) — 1,278 citations
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. (2006) — 897 citations
- Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. (2006) — 826 citations